Selpercatinib Active substance SelpercatinibDomain Oncology and HematologyReason of inclusion in Horizonscan Geneesmiddelen New medicine (specialité)Main indication Thyroid cancerExtended indication Patients With RET-Mutant Medullary Thyroid Cancer 1. Product Manufacturer Eli LillyMechanism of action Tyrosine kinase inhibitorRoute of administration OralTherapeutical formulation CapsuleBudgetting framework Intermural (MSZ)Additional comments Tyrosine kinase inhibitor met antineoplastische eigenschappen. Potente, selectieve remmer van de RET-kinase, ontwikkeld om de ATP-bindingsite vd RET-kinase te blokkeren. Zo wordt de ‘down stream’ signalling pathway geremd. 2. Registration Registration route Centralised (EMA)Submission date February 2020Expected Registration March 2021Orphan drug NoRegistration phase Registration application pending 3. Therapeutic value Current treatment options RET fusie-positieve NSCLC: Carboplatin/Cisplatin + Pemetrexed +/- Pembrolizumab.RET-gemuteerde medullaire thyroïd kanker: Cabozantinib/vandetanibTherapeutic value No judgementDuration of treatment Not foundFrequency of administration 2 times a dayReferences NCT04211337 (LIBRETTO-531) 4. Expected patient volume per year There is currently nothing known about the expected patient volume. 5. Expected cost per patient per year There is currently nothing known about the expected cost. 6. Potential total cost per year There is currently nothing known about the possible total cost. 7. Off label use There is currently nothing known about off label use. 8. Indication extension Indication extension NoReferences adisinsight 9. Other information There is currently no futher information available.